in

The world’s leading pharmaceutical company: AstraZeneca (AZN)

AstraZeneca Pharmaceuticals (AstraZeneca Pharmaceuticals) AstraZeneca PLC (LSE: AZN, OMX: AZN, NYSE: AZN) is headquartered in London, England, and employs 70,600 people worldwide. It is a company owned by Astra AB (Astra AB, Sweden). ) And the British Zeneca Group PLC (Zeneca Group PLC) merged on April 6, 1999 to form a large-scale British-Swiss joint venture pharmaceutical company. AstraZeneca develops, manufactures and sells drugs for the treatment of digestive, cardiovascular, tumor, central nervous, respiratory diseases and anesthesia.

AstraZeneca AZN Logo

AstraZeneca (AZN):

AstraZeneca is the world’s leading pharmaceutical company, providing patients with innovative and effective pharmaceutical products in 6 major therapeutic areas, including: digestive diseases, cardiovascular diseases, cancer, central nervous system diseases, anesthesia and respiratory diseases, etc. Many of these products are in the leading position in the world.

AstraZeneca Pharmaceuticals is headquartered in London, England, and its R&D headquarters is located in Sodertalje, Stockholm Province, Sweden. It is a component of the FTSE 100 Index. It became the No. 1 listed on the London Stock Exchange with a market capitalization of 54.8 billion on August 1, 2014. The six companies are the largest multinational pharmaceutical companies in China’s prescription drug market.

AstraZeneca (AZN) product:

  • Tumor drugs: Norride (Goserelin Acetate), Constad (Bicalutamide), Nolvadex (Tamoxifen Citrate) and Rimid (Anastrozole)
  • Digestive drugs: Losec (Ogilvy)-the world’s largest selling drug
  • Cardiovascular drugs: Betaloc (Metoprolol Tartrate), Poidin (Felodipine), Ramace (Ramipril) and Atacand (Dihydrochlorothiazide), Gestrel (Lisinopril) and Tenormin (Atenolol)
  • Respiratory drugs: Pulmicort (Budesonide), Bolicanil (terbutaline sulfate), Reynoldscott (Budesonide), Encolate (Zalurukast, which is an oral leukotriene receptor Body antagonist (LTRA), for maintenance treatment of asthma) and inhaler propellant
  • Central nervous system drugs: Zomig (Zolmitriptan)
  • Anesthetics: Xerocaine (lidocaine)-the world’s largest-selling local anesthetic, Diprima (propofol)-the world’s largest-selling injectable conventional anesthetic
  • Agricultural chemical products: Ke Wuxi, Fusilade, Touchdown and Surpass (herbicide), Karate (insecticide), Amistar (fungicide)

Product full picture:

AstraZeneca Products 1

Click to see larger picture

AstraZeneca (AZN) History:

  • In 1913, 400 doctors and pharmacists founded Astra AB in Sweden, one of the predecessors of AstraZeneca;
  • In 1993, the British company Imperial Chemical Industries (ICI) spun off its pharmaceutical, agricultural chemicals and specialty products business and established Zeneca Group plc, another predecessor of AstraZeneca;
  • On April 6, 1999, Astra AB and Zeneca Group plc merged to form AstraZeneca plc;
  • In 2005, AstraZeneca acquired the British biotechnology company KuDOS Pharmaceuticals for 120 million pounds, and reached an anti-cancer collaboration agreement with Astex;
  • In 2006, AstraZeneca acquired Cambridge Antibody Technology for £702 million;
  • In February 2007, AstraZeneca acquired Arrow Therapeutics for USD 150 million;
  • On April 23, 2007, AstraZeneca acquired MedImmune for USD 15.2 billion , obtaining a combination of infant influenza vaccines and antiviral treatment products. AstraZeneca subsequently integrated all of its biological products operations into a dedicated biological products department-MedImmune;
  • In 2010, AstraZeneca acquisition of antibiotic research and development company Novexel Corp (2004 Nian by the Sanofi peel (Sanofi-Aventis) anti-infective department was established);
  • In 2011, AstraZeneca acquired the Chinese genetic engineering company Guangdong BeiKang Pharmaceutical Company;
  • In February 2012, AstraZeneca and Amgen announced a collaboration to treat inflammatory diseases;
  • In April 2012, AstraZeneca acquired the biotechnology company Ardea Biosciences for US$1.24 billion;
  • In June 2012, AstraZeneca and Bristol-Myers Squibb announced a two-step agreement to jointly acquire biotechnology company Amylin Pharmaceuticals. The agreement includes: Bristol-Myers Squibb acquires Amylin for US$5.3 billion in cash and assumes US$1.7 billion in debt, AstraZeneca pays US$3.4 billion in cash to Bristol-Myers Squibb, and Amylin is injected into AstraZeneca and Bristol-Myers Squibb Existing joint ventures on diabetes cooperation;
  • In 2013, AstraZeneca restructured its organizational structure and planned to move its headquarters from London to Cambridge in 2016. After the reorganization, the company will focus on 3 areas: (1) Respiratory tract, inflammation and autoimmunity; (2) Cardiovascular and metabolic diseases; (3) Tumor;
  • In October 2013, AstraZeneca announced the acquisition of Spirogen, a biotechnology oncology company, for US$440 million;
  • On May 19, 2014, AstraZeneca rejected Pfizer ’s “final offer” of £55 per share, valued at £69.4 billion (US$117 billion);
  • In July 2014, AstraZeneca reached an agreement with Almirall to acquire its subsidiary Almirall Sofotec and its lung treatments, including COPD drug Eklira, for US$2.1 billion;
  • In August 2014, AstraZeneca announced a three-year cooperation with Mitsubishi Tanabe Pharma on diabetic nephropathy;
  • In September 2014, AstraZeneca cooperated with Eli Lilly to develop and commercialize its product candidate-BACE inhibitor-AZD3292 for the treatment of Alzheimer’s disease. The transaction may bring the company up to 500 million US dollars;
  • In November 2014, MedImmune, AstraZeneca’s biological product research and development department, agreed to acquire Definiens for more than US$150 million;
  • In November 2014, AstraZeneca agreed to sell its lipodystrophy treatment business to Aegerion Pharmaceuticals for more than US$325 million;
  • In February 2015, AstraZeneca announced the acquisition of the rights of Actavis brand respiratory medicines in the United States and Canada for approximately US$600 million;
  • In February 2015, AstraZeneca announced the cooperation with Orca Pharmaceuticals to develop retinoic acid-related orphan nuclear receptor gamma inhibitors for the treatment of some autoimmune diseases, which could bring Orca up to 122.5 million US dollars;
  • In mid-March 2015, AstraZeneca announced that it would jointly commercialize naloxegol with Daiichi Sankyo (TYO:4568, NASDAQ:DSNKY), valued at US$825 million;
  • As of the end of April 2015, AstraZeneca announced a cooperation value of approximately US$1.8 billion, including the development and commercialization of MEDI4736 with Celgene for non-Hodgkin’s lymphoma, myelodysplastic syndromes and multiple myeloma; the company’s Medimmune The department also launched a collaborative clinical trial with Juno Therapeutics to study the combined treatment of cancer;
  • In late June 2015, AstraZeneca announced that it had reached a cooperation agreement with Eolas Therapeutics on Eolas Orexin-1 receptor antagonist (EORA) smoking cessation and other treatment options;
  • In July 2015, AstraZeneca announced that it would sell its rights to Entocort (Budesonide) to Tillotts Pharma for $215 million;
  • In July 2015, Genzyme announced that it would acquire the rare cancer drug Caprelsa (vandetanib) from AstraZeneca for US$300 million;
  • In August 2015, AstraZeneca announced that it had acquired the global development and commercialization rights of Heptares Therapeutics drug candidate HTL-1071 for US$510 million, which focuses on blocking adenosine A2A receptors;
  • In August 2015, the company’s MedImmune subsidiary acquired Inovio Pharmaceuticals’ exclusive rights to INO-3112 immunotherapy for more than US$727.5 million under an agreement;
  • On November 6, 2015, AstraZeneca acquired ZS Pharma for US$2.7 billion;
  • On December 16, 2015, AstraZeneca spent US$575 million to acquire Takeda Pharmaceutical ’s core respiratory medicine business, including the drug Daliresp (Daxas), which can prevent chronic obstructive pulmonary disease;
  • On December 17, 2015, AstraZeneca spent US$4 billion to acquire a 55% interest in the unlisted biopharmaceutical company Acerta Pharma in order to obtain a new drug for the treatment of leukemia from the latter;
  • On August 24, 2016, AstraZeneca stated that it had agreed to sell part of its antibiotic business to Pfizer Pharmaceuticals Co. , Ltd. for a price of US$1.575 billion plus patent licensing fees. The transaction involved three approved antibiotics and two drugs that are still in clinical trials. In the future, Pfizer will have the right to sell these drugs in most markets outside the United States. The assets sold by AstraZeneca do not include its biological anti-infective drugs;
  • On March 29, 2019, AstraZeneca Pharmaceuticals invested US$6.9 billion and Japan’s Daiichi Sankyo to jointly develop cancer treatment drugs to enhance its position in the oncology medicine market.

Schematic diagram of the acquisition history of AstraZeneca (AZN):

AstraZeneca Acquisition history

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

The world’s oldest and largest art auction house: Sotheby’s (BID) (774)

The largest video game retailer in North America: Game Station GameStop (GME) (1994)